Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Common medication gets first major test in dialysis patients

NCT ID NCT03977207

Summary

This study is testing whether a thyroid medication called levothyroxine improves quality of life and heart health in people receiving dialysis. Researchers will enroll 336 dialysis patients who have borderline thyroid levels and randomly assign them to receive either the medication or a placebo for six months. The main goals are to see if the medication helps patients feel better physically and slows the progression of heart artery calcification.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMODIALYSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California Irvine

    RECRUITING

    Orange, California, 92868, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.